Although antibodies to PD-L1 are used in the clinic, their benefit is limited by immune exclusion within the local microenvironment. Objective response rates with anti-PD-L1 monotherapy are low due to the heterogeneity of PD-L1 expression, low tumor mutational burden and the highly immunosuppressive tumor microenvironment (TME) of cholangiocarcinoma (CCA).
Elevar Therapeutics Inc. appointed Kim Dong-gun (DG) as CEO Jan. 29, as the company focuses on post-NDA strategies for lirafugratinib in bile duct cancer, and the twice-rejected rivoceranib-camrelizumab combination for liver cancer.
Elevar Therapeutics Inc. appointed Kim Dong-gun (DG) as CEO Jan. 29, as the company focuses on post-NDA strategies for lirafugratinib in bile duct cancer, and the twice-rejected rivoceranib-camrelizumab combination for liver cancer.
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in this disease.
Transthera Sciences Inc. debuted on the Hong Kong stock exchange June 23 with a HK$200.95 million (US$25.6 million) IPO, becoming the latest in a string of mainland Chinese biopharmaceutical firms to turn to the Hong Kong market for capital.
Transthera Sciences Inc. debuted on the Hong Kong stock exchange June 23 with a HK$200.95 million (US$25.6 million) IPO, becoming the latest in a string of mainland Chinese biopharmaceutical firms to turn to the Hong Kong market for capital.
Cholangiocarcinoma is a rare cancer that arises from the intrahepatic biliary epithelium or extrahepatic bile ducts. Apart from genetic mutations, epigenetic changes are also contributing to cancer development, making DNA methylation and histone modification focus for cancer research.
Abnormal fusion of the FGFR2 gene, encoding the fibroblast growth factor receptor 2, occurs in several types of cancer, including in up to 15% of cases of intrahepatic cholangiocarcinoma.
Cholangiocarcinoma includes several biliary malignant tumors that have poor prognosis. Post-translational modifications in proteins lead to abnormal protein dynamics and disturbances that may cause pathology.
-CEO-Elevar-1-30.webp?height=488&t=1769801176&width=650 "Kim Dong-gun (DG), CEO, Elevar")
